Wall Street brokerages expect Strongbridge Biopharma plc (NASDAQ:SBBP) to report $2.98 million in sales for the current quarter, according to Zacks. Three analysts have made estimates for Strongbridge Biopharma’s earnings, with estimates ranging from $2.43 million to $3.29 million. The firm is scheduled to announce its next quarterly earnings report on Monday, March 26th.

On average, analysts expect that Strongbridge Biopharma will report full year sales of $2.98 million for the current fiscal year, with estimates ranging from $6.49 million to $7.35 million. For the next financial year, analysts forecast that the company will post sales of $14.04 million per share, with estimates ranging from $9.39 million to $21.91 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover Strongbridge Biopharma.

A number of brokerages have recently commented on SBBP. BidaskClub raised shares of Strongbridge Biopharma from a “hold” rating to a “buy” rating in a report on Wednesday, December 27th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Strongbridge Biopharma in a report on Wednesday, December 6th. Zacks Investment Research cut shares of Strongbridge Biopharma from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of Strongbridge Biopharma in a report on Wednesday, November 15th. Finally, ValuEngine cut shares of Strongbridge Biopharma from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $12.81.

Strongbridge Biopharma (NASDAQ SBBP) opened at $7.70 on Friday. The company has a market cap of $300.58 and a price-to-earnings ratio of -2.28. Strongbridge Biopharma has a 1-year low of $2.10 and a 1-year high of $8.85. The company has a debt-to-equity ratio of -1.89, a current ratio of 4.70 and a quick ratio of 4.61.

Institutional investors and hedge funds have recently made changes to their positions in the business. State of Wisconsin Investment Board acquired a new position in Strongbridge Biopharma in the 2nd quarter valued at $114,000. Rhumbline Advisers acquired a new position in Strongbridge Biopharma in the 2nd quarter valued at $154,000. California State Teachers Retirement System acquired a new position in Strongbridge Biopharma in the 2nd quarter valued at $277,000. Teachers Advisors LLC acquired a new position in Strongbridge Biopharma in the 2nd quarter valued at $297,000. Finally, Bank of New York Mellon Corp acquired a new position in Strongbridge Biopharma in the 2nd quarter valued at $331,000. 57.53% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.thecerbatgem.com/2018/01/06/strongbridge-biopharma-plc-sbbp-expected-to-post-quarterly-sales-of-2-98-million.html.

Strongbridge Biopharma Company Profile

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Get a free copy of the Zacks research report on Strongbridge Biopharma (SBBP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related stocks with our FREE daily email newsletter.